Michael B. Atkins

93.9k total citations · 18 hit papers
577 papers, 40.7k citations indexed

About

Michael B. Atkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael B. Atkins has authored 577 papers receiving a total of 40.7k indexed citations (citations by other indexed papers that have themselves been cited), including 368 papers in Oncology, 280 papers in Pulmonary and Respiratory Medicine and 214 papers in Molecular Biology. Recurrent topics in Michael B. Atkins's work include Renal cell carcinoma treatment (239 papers), Cancer Immunotherapy and Biomarkers (224 papers) and CAR-T cell therapy research (129 papers). Michael B. Atkins is often cited by papers focused on Renal cell carcinoma treatment (239 papers), Cancer Immunotherapy and Biomarkers (224 papers) and CAR-T cell therapy research (129 papers). Michael B. Atkins collaborates with scholars based in United States, United Kingdom and France. Michael B. Atkins's co-authors include David F. McDermott, John M. Kirkwood, Arthur J. Sober, Geoffrey T. Gibney, Brian I. Rini, Janice P. Dutcher, James W. Mier, John F. Thompson, Charles M. Balch and Daniel G. Coit and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Michael B. Atkins

565 papers receiving 39.8k citations

Hit Papers

Final Version of 2009 AJC... 1997 2026 2006 2016 2009 2001 2001 2009 1999 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of 2009 AJCC Melanoma Staging and Classification
    2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  2. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
    2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
  3. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
    2001 1.8k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  4. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
    2009 1.5k citations David F. McDermott, Michael B. Atkins et al. Journal of Clinical Oncology profile →
  5. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
    1999 1.5k citations Michael B. Atkins, Janice P. Dutcher et al. Journal of Clinical Oncology profile →
  6. Predictive biomarkers for checkpoint inhibitor-based immunotherapy
    2016 1.3k citations Michael B. Atkins et al. profile →
  7. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
    2004 742 citations Michael B. Atkins, Janice P. Dutcher et al. Journal of Clinical Oncology profile →
  8. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
    1997 684 citations Matthew L. Sherman, Michael B. Atkins et al. profile →
  9. Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion
    2005 671 citations Arnold H. Zea, Paulo C. Rodrı́guez et al. Cancer Research profile →
  10. Management of Cutaneous Melanoma
    2004 654 citations Michael B. Atkins, Arthur J. Sober et al. profile →
  11. Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
    2009 634 citations Paulo C. Rodrı́guez, Marc S. Ernstoff et al. Cancer Research profile →
  12. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
    2004 598 citations John M. Kirkwood, Marc S. Ernstoff et al. Journal of Clinical Oncology profile →
  13. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
    2008 534 citations Vernon K. Sondak, Michael B. Atkins et al. Journal of Clinical Oncology profile →
  14. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    2020 498 citations Elizabeth R. Plimack, Ray McDermott et al. profile →
  15. Toxicities of Immunotherapy for the Practitioner
    2015 465 citations Michael B. Atkins et al. Journal of Clinical Oncology profile →
  16. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
    2019 409 citations Suzanne L. Topalian, F. Stephen Hodi et al. profile →
  17. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. profile →
  18. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
    2021 183 citations David F. McDermott, Rodolfo F. Perini et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael B. Atkins 25.3k 16.0k 12.6k 12.0k 6.3k 577 40.7k
Keith T. Flaherty 24.8k 1.0× 23.3k 1.5× 6.3k 0.5× 7.1k 0.6× 5.7k 0.9× 518 39.7k
John M. Kirkwood 31.3k 1.2× 17.9k 1.1× 4.4k 0.4× 18.8k 1.6× 3.9k 0.6× 687 46.4k
F. Stephen Hodi 34.2k 1.4× 10.4k 0.7× 9.8k 0.8× 16.7k 1.4× 3.4k 0.5× 517 44.0k
Julie R. Brahmer 29.2k 1.2× 7.7k 0.5× 18.7k 1.5× 7.6k 0.6× 4.7k 0.7× 355 38.4k
Jedd D. Wolchok 45.3k 1.8× 16.2k 1.0× 11.0k 0.9× 29.7k 2.5× 4.6k 0.7× 568 65.0k
David L. Rimm 19.9k 0.8× 17.9k 1.1× 7.9k 0.6× 7.0k 0.6× 8.2k 1.3× 547 41.4k
Antoni Ribas 39.7k 1.6× 27.4k 1.7× 7.5k 0.6× 22.6k 1.9× 6.3k 1.0× 551 61.0k
Jean‐Charles Soria 19.7k 0.8× 13.0k 0.8× 12.8k 1.0× 4.7k 0.4× 6.8k 1.1× 679 34.8k
Richard Pazdur 19.8k 0.8× 10.6k 0.7× 10.3k 0.8× 3.7k 0.3× 5.2k 0.8× 596 37.7k
Howard A. Burris 25.4k 1.0× 13.0k 0.8× 10.7k 0.8× 3.3k 0.3× 6.2k 1.0× 741 38.2k

Countries citing papers authored by Michael B. Atkins

Since Specialization
Citations

This map shows the geographic impact of Michael B. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Atkins more than expected).

Fields of papers citing papers by Michael B. Atkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael B. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Atkins. The network helps show where Michael B. Atkins may publish in the future.

Co-authorship network of co-authors of Michael B. Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of Michael B. Atkins. A scholar is included among the top collaborators of Michael B. Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael B. Atkins. Michael B. Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deutsch, Julie S., Evan J. Lipson, Ludmila Danilova, et al.. (2023). Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Reports Medicine. 4(2). 100947–100947. 18 indexed citations
2.
Denize, Thomas, Yue Hou, Jean‐Christophe Pignon, et al.. (2022). Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 28(18). 4045–4055. 13 indexed citations
3.
Gupta, Samir, Anas Belouali, Neil J. Shah, Michael B. Atkins, & Subha Madhavan. (2021). Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. JCO Clinical Cancer Informatics. 5(5). 541–549. 16 indexed citations
4.
Martini, Jean-François, Elizabeth R. Plimack, Toni K. Choueiri, et al.. (2020). Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 26(21). 5598–5608. 16 indexed citations
5.
Xu, Wenxin, Mäneka Puligandla, Judith Manola, et al.. (2019). Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research. 25(20). 6098–6106. 11 indexed citations
6.
Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815. 48 indexed citations
7.
Tannir, Nizar M., Sumanta K. Pal, & Michael B. Atkins. (2018). Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. The Oncologist. 23(5). 540–555. 55 indexed citations
8.
Mays, Darren, Michael B. Atkins, Jaeil Ahn, & Kenneth P. Tercyak. (2017). Indoor Tanning Dependence in Young Adult Women. Cancer Epidemiology Biomarkers & Prevention. 26(11). 1636–1643. 11 indexed citations
9.
Butterfield, Lisa H., Fengmin Zhao, Charles Lee, et al.. (2017). Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clinical Cancer Research. 23(17). 5034–5043. 35 indexed citations
10.
Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565. 21 indexed citations
11.
Erbe, Amy K., Wei Wang, Jacob L. Goldberg, et al.. (2016). FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 23(9). 2159–2168. 12 indexed citations
12.
Callea, Marcella, Laurence Albigès, Mamta Gupta, et al.. (2015). Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research. 3(10). 1158–1164. 266 indexed citations
13.
Haas, Naomi B., Judith Manola, Bonnie Ky, et al.. (2015). Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clinical Cancer Research. 21(18). 4048–4054. 46 indexed citations
14.
Wang, Xiaoen, Andrea J. Bullock, Marcella Callea, et al.. (2015). Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research. 21(8). 1925–1934. 67 indexed citations
15.
Manola, Judith, Patrick Royston, Paul Elson, et al.. (2011). Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. Clinical Cancer Research. 17(16). 5443–5450. 148 indexed citations
16.
Bhatt, Rupal S., Xiaoen Wang, Liang Zhang, et al.. (2010). Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. Molecular Cancer Therapeutics. 9(10). 2793–2802. 48 indexed citations
17.
Cho, Daniel C., David J. Panka, Michael P. Collins, et al.. (2010). The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research. 16(14). 3628–3638. 154 indexed citations
18.
Rodrı́guez, Paulo C., Marc S. Ernstoff, Claudia Hernandez, et al.. (2009). Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes. Cancer Research. 69(4). 1553–1560. 634 indexed citations breakdown →
19.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2009). Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 27(36). 6199–6206. 3342 indexed citations breakdown →
20.
Zea, Arnold H., Paulo C. Rodrı́guez, Michael B. Atkins, et al.. (2005). Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. Cancer Research. 65(8). 3044–3048. 671 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keith T. Flaherty Breakdown of academic impact, for papers by John M. Kirkwood Breakdown of academic impact, for papers by F. Stephen Hodi Breakdown of academic impact, for papers by Julie R. Brahmer Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by David L. Rimm Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Jean‐Charles Soria Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Howard A. Burris
Rankless by CCL
2026